View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
July 25, 2022

Europe’s medical devices industry saw a rise of 25.64% in deal activity during June 2022

By Carmen

Europe’s medical devices industry saw a rise of 25.64% in deal activity during June 2022, when compared with the last 12-month average, led by ResMed’s $1bn acquisition of MediFox DAN Group, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 49 medical devices industry deals worth $2.2bn were announced for the region in June 2022, against the 12-month average of 39 deals.

Of all the deal types, venture financing saw most activity in June 2022 with 25 transactions, representing a 51.02% share for the region.

In second place was M&A with 19 deals, followed by private equity deals with five transactions, respectively capturing a 38.8% and 10.2% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $1.14bn, while private equity and venture financing deals totalled $843.97m and $198.66m, respectively.

Europe medical devices industry deals in June 2022: Top deals

The top five medical devices deals accounted for 91.9% of the overall value during June 2022.

The combined value of the top five medical devices deals stood at $2.01bn, against the overall value of $2.2bn recorded for the month.

The top five medical devices industry deals of June 2022 tracked by GlobalData were:

1) ResMed $1bn acquisition deal with MediFox DAN Group

2) The $797.86m private equity of SPT Labtech by EQT IX Fund

3) Azenta $85.5m acquisition deal with Barkey GmbHKG

4) The $80m venture financing of Proximie by Advent Life Sciences,British Patient Capital,Eight Roads Ventures,Emerson Collective,F Prime Capital,Global ventures,Maverick Ventures Israel,Minderoo Foundation,Mubadala Investment,Questa Capital Management and SoftBank Vision Fund 2

5) Fujirebio $42.15m acquisition deal with ADx NeuroSciences

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network